Literature DB >> 34409580

Influences of Stent Design on In-Stent Restenosis and Major Cardiac Outcomes: A Scoping Review and Meta-Analysis.

Omer Burak Istanbullu1, Gulsen Akdogan2.   

Abstract

Thanks to the developments in implantable biomaterial technologies, invasive operating procedures, and widespread applications especially in vascular disease treatment, a milestone for interventional surgery was achieved with the introduction of vascular stents. Despite vascular stents providing a solution for embolisms, this technology includes various challenges, such as mechanical, electro-chemical complications, or in-stent restenosis (ISR) risks with long-term usage. Therefore, further development of biomaterial technologies is vital to overcome such risks and problems. For this purpose, recent research has focused mainly on the applications of surface modification techniques on biomaterials and vascular stents to increase their hemocompatibility. ISR risk has been reduced with the development and prevalent usage of the art technology stent designs of drug-eluting and biodegradable stents. Nevertheless, their problems have not been overcome completely. Furthermore, patients using drug-eluting stents are faced with further clinical challenges. Therefore, the bare metal stent, which is the first form of the vascular stent technology and includes the highest ISR risk, is still in common usage for vascular treatment applications. For this reason, further research is necessary to solve the remaining vital problems. In this scoping review, stent-based major cardiac events including ISR are analyzed depending on different designs and material selection in stent manufacturing. Recent and novel approaches to overcome such challenges are stated in detail.
© 2021. Biomedical Engineering Society.

Entities:  

Keywords:  Bare-metal stent; Biodegradable stent; Biomaterials; Drug-eluting stent; In-stent restenosis; Surface modification; Vascular occlusion

Mesh:

Substances:

Year:  2021        PMID: 34409580     DOI: 10.1007/s13239-021-00569-0

Source DB:  PubMed          Journal:  Cardiovasc Eng Technol        ISSN: 1869-408X            Impact factor:   2.495


  105 in total

1.  Characterization of post-operative risk associated with prior drug-eluting stent use.

Authors:  Saif Anwaruddin; Arman T Askari; Hammad Saudye; Lilian Batizy; Penny L Houghtaling; Mohammad Alamoudi; Michael Militello; Kamran Muhammad; Samir Kapadia; Stephen G Ellis
Journal:  JACC Cardiovasc Interv       Date:  2009-06       Impact factor: 11.195

2.  Incidence and mechanisms of longitudinal stent deformation associated with Biomatrix, Resolute, Element, and Xience stents: Angiographic and case-by-case review of 1,800 PCIs.

Authors:  Samer Arnous; Nizar Shakhshir; Andrew Wiper; Farzin-Farth Ordoubadi; Paul Williams; Bernard Clarke; Vaikom Mahadavan; Magdi El-Omar; Mamas Mamas; Douglas Fraser
Journal:  Catheter Cardiovasc Interv       Date:  2015-04-24       Impact factor: 2.692

3.  Implantation of a drug-eluting stent with a different drug (switch strategy) in patients with drug-eluting stent restenosis. Results from a prospective multicenter study (RIBS III [Restenosis Intra-Stent: Balloon Angioplasty Versus Drug-Eluting Stent]).

Authors:  Fernando Alfonso; Maria J Pérez-Vizcayno; Jaime Dutary; Javier Zueco; Angel Cequier; Arturo García-Touchard; Vicens Martí; Iñigo Lozano; Juan Angel; José M Hernández; José R López-Mínguez; Rafael Melgares; Raúl Moreno; Bernhard Seidelberger; Cristina Fernández; Rosana Hernandez
Journal:  JACC Cardiovasc Interv       Date:  2012-07       Impact factor: 11.195

Review 4.  Current treatment of in-stent restenosis.

Authors:  Fernando Alfonso; Robert A Byrne; Fernando Rivero; Adnan Kastrati
Journal:  J Am Coll Cardiol       Date:  2014-03-13       Impact factor: 24.094

5.  A randomized comparison of drug-eluting balloon versus everolimus-eluting stent in patients with bare-metal stent-in-stent restenosis: the RIBS V Clinical Trial (Restenosis Intra-stent of Bare Metal Stents: paclitaxel-eluting balloon vs. everolimus-eluting stent).

Authors:  Fernando Alfonso; Maria Jose Pérez-Vizcayno; Alberto Cárdenas; Bruno García Del Blanco; Bernhard Seidelberger; Andrés Iñiguez; Manuel Gómez-Recio; Mónica Masotti; M Teresa Velázquez; Juan Sanchís; Arturo García-Touchard; Javier Zueco; Armando Bethencourt; Rafael Melgares; Angel Cequier; Antonio Dominguez; Vicente Mainar; José R López-Mínguez; José Moreu; Vicens Martí; Raúl Moreno; Pilar Jiménez-Quevedo; Nieves Gonzalo; Cristina Fernández; Carlos Macaya
Journal:  J Am Coll Cardiol       Date:  2014-01-08       Impact factor: 24.094

6.  Optical coherence tomography study of healing characteristics of paclitaxel-eluting balloons vs. everolimus-eluting stents for in-stent restenosis: the SEDUCE (Safety and Efficacy of a Drug elUting balloon in Coronary artery rEstenosis) randomised clinical trial.

Authors:  Tom Adriaenssens; Jo Dens; Giovanni Ughi; Johan Bennett; Christophe Dubois; Peter Sinnaeve; Stefanus Wiyono; Mark Coosemans; Ann Belmans; Jan D'hooge; Mathias Vrolix; Walter Desmet
Journal:  EuroIntervention       Date:  2014-08       Impact factor: 6.534

Review 7.  Lasers for caries removal in deciduous and permanent teeth.

Authors:  Alessandro Montedori; Iosief Abraha; Massimiliano Orso; Potito Giuseppe D'Errico; Stefano Pagano; Guido Lombardo
Journal:  Cochrane Database Syst Rev       Date:  2016-09-26

8.  Zinc reduces intimal hyperplasia in the rat carotid injury model.

Authors:  Michael Berger; Esthie Rubinraut; Iris Barshack; Arie Roth; Gad Keren; Jacob George
Journal:  Atherosclerosis       Date:  2004-08       Impact factor: 5.162

9.  New biliary and pancreatic biodegradable stent placement: a single-center, prospective, pilot study (with video).

Authors:  Andrea Anderloni; Alessandro Fugazza; Luca Maroni; Vittorio Ormando; Roberta Maselli; Silvia Carrara; Annalisa Cappello; Benedetto Mangiavillano; Paolo Omodei; Paoletta Preatoni; Piera Alessia Galtieri; Gaia Pellegatta; Alessandro Repici
Journal:  Gastrointest Endosc       Date:  2020-03-05       Impact factor: 9.427

10.  A Randomized Comparison of Paclitaxel-Eluting Balloon Versus Everolimus-Eluting Stent for the Treatment of Any In-Stent Restenosis: The DARE Trial.

Authors:  Jan Baan; Bimmer E Claessen; Kirsten Boerlage-van Dijk; Jeroen Vendrik; René J van der Schaaf; Martijn Meuwissen; Niels van Royen; A T Marcel Gosselink; Marleen H van Wely; Atilla Dirkali; E Karin Arkenbout; Robbert J de Winter; Karel T Koch; Krischan D Sjauw; Marcel A Beijk; M Marije Vis; Joanna J Wykrzykowska; Jan J Piek; Jan G P Tijssen; José P S Henriques
Journal:  JACC Cardiovasc Interv       Date:  2017-11-07       Impact factor: 11.195

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.